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ABSTRACT
Background: Despite calls for advance community distribution of Misoprostol, World Health Organization is 
cautious about recommending this. This report highlights complications of Misoprostol use by community birth 
attendants, discusses implications of advance distribution and possible solutions. 
Case Report: Labour induced in a woman attending a facility run by a nurse using high dose (300mcg) misoprostol 
and another drug resulted in her infant developing severe birth asphyxia immediately after delivery.
Conclusion: Misuse of Misoprostol leads to complications. Research into community usage, confidential enquiries, 
development of guidelines and training of birth attendants is needed.  Production of low dose Misoprostol (25mcg) 
should be encouraged.
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In January 2006, Nigeria became the first country in 
the world to register misoprostol for the prevention 
and treatment of Postpartum Haemorrhage (PPH) 
which is a major cause of maternal mortality 
1,2worldwide . This followed studies in several 
countries which showed that community birth 
attendants and even birthing women themselves 
can administer misoprostol safely and reduce the 
,3-6incidence and severity of PPH .  Misoprostol is 
cheap, heat stable, with a long shelf life and can be 
administered orally, vaginally, sublingually, or 
7
rectally .  Thus various world authorities e.g. the 
World Health Organization (WHO), the 
International Federation of Obstetrics and 
Gynaecology (FIGO) and the International 
Confederation of Midwives (ICM) have 
recommended its use by birth attendants who may 
not have the required skills or resources to manage 
8,9
serious bleeding . 
Some workers have also advocated for routine 
distribution of misoprostol to birth attendants and 
pregnant women in the community before 
10,11delivery . (Potts et al in a commentary in the 
Lancet argued that this practice (known as advance 
provision of misoprostol) could lead to fewer 
maternal deaths, improvement in maternal health 
and the achievement of Millennium Development 
9Goal 5 .  However WHO is cautious about 
recommending advance distribution because of the 
possibility of harmful effects even though 
Misoprostol is included in its Model List of Essential 
Medicines for use in PPH and incomplete 
1 2 , 1 3
abortion .  Misoprostol is a synthetic 
prostaglandin E analogue which was originally 
developed for the treatment of peptic ulcer disease 
but because it causes myometrial contractions it has 
also been used for cervical ripening and induction of 
7
labour . The following case report highlights a 
complication of use of misoprostol in the 
community, discusses the implications of 
community distribution and offers possible 
solutions. 
CASE REPORT
A male infant was rushed to a private hospital with a 
history of recurrent convulsions and failure to cry or 
suck since birth. He had been delivered 24 hours 
earlier to a Para 2+0, 31year old woman at a facility 
run by a nurse. (The baby's mother stated that she had 
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delivered twice vaginally in the same facility - her 
first child weighing 4.5kg at birth). 
During the index patient's pregnancy, the mother had 
received antennal care at the same maternity home 
and had reportedly had an uneventful pregnancy. 
However she was induced because she was past her 
date of delivery using tablets which she identified as 
misoprostol 200mcg.  One tablet of Misoprostol was 
broken into two, and half (100mcg) inserted 
vaginally, while the other half (100mcg) had been 
given to her sublingually. After an hour another 100 
mcg was inserted vaginally because contractions had 
not yet commenced. Shortly after, she started 
contracting but a “hot drip” (name unknown) was 
added because her contractions were weak. She then 
developed strong contractions and delivered 
vaginally a few hours later. She stated that the baby 
turned black immediately after birth and did not cry 
even when resuscitated with oxygen and given 
antibiotics. He was kept in the maternity home until 
he started convulsing at which point he was referred.
The child was found to be dyspnoeic, peripherally 
cyanosed with normal facies and a weight of 3.5kg. 
He was afebrile, not pale, and anicteric. Gestational 
age was assessed to be 40+2 weeks. He had a patent, 
non-bulging anterior fontanelle.  A diagnosis of 
severe birth asphyxia was made and he was admitted 
for intensive care. Transfontanelle ultrasound 
showed no structural abnormality and no 
intracerebral haemorrhage. Blood sugar was normal, 
HIV antibodies were non-reactive and VDRL 
negative. Apart from a relative neutrophilia and a 
mild increase in urea level, his other investigations 
were normal apart.  His condition eventually 
improved and he was discharged after three weeks. 
When last seen at the age of 4 weeks, his convulsions 
had ceased and he was able to cry and suck a little but 
his weight had dropped to 3.1kg. His parents were 
counselled about the possibility of neurological 
damage and the need for regular follow up. 
DISCUSSION
The patient described in this report developed severe 
birth asphyxia following induction of labour by a 
private birth attendant in the community who used 
high doses of Misoprostol in combination with 
another drug that also enhanced uterine contractility 
and led to hypertonic uterine action. WHO and other 
authorities recommend low doses of Misoprostol be 
used for induction (e.g. 25mcg Misoprostol every 2 
hours or 50mcg every 4 hours till labour is 
14
established) . If another uterotonic is needed, it 
should not be given till six hours after the last dose of 
Misoprostol is administered. Thus Misoprostol was 
used inappropriately. When administered 
sublingually, Misoprostol is quickly absorbed into 
the blood stream and continues to act for at least 2 
hours. Absorption is slower when given vaginally. 
Maximum plasma levels are not reached till 70 to 80 
minutes later but the drug is still detectable in the 
7plasma after 6 hours . It is likely that in the patient's 
mother, the maximal effect of Misoprostol did not 
occur till when the drip was started probably leading 
to a combined effect of two uterotonics. The effect of 
high doses of uterotonics results in hyperstimulation 
of the uterus, interruption of oxygen delivery to the 
foetus and resultant intrapartum asphyxia. 
The qualifications and training of the birth attendant 
could not be ascertained. Very often informal health 
workers who have no orthodox medical training are 
referred to as “doctors” or “nurses” by their clients. 
But there are facilities which are run by qualified 
nurses and midwives and which are supposed to be 
15supervised by a doctor .  The contents of the “hot 
drip'' could also not be determined though it 
obviously contained a substance that increased 
uterine contraction, possibly oxytocin. 
The mother of the child in this report was a 
multiparous woman. Misoprostol has been used for 
induction in grand multipara but strict vigilance and 
close monitoring of both mother and foetus during 
14
labour is necessary . Complications of use include 
uterine hyperstimulation, ruptured uterus, foetal 
16-22
tachycardia, birth asphyxia and neonatal death . 
These occur more commonly when higher doses are 
16-22
used . A survey of doctors in Nigeria who have 
used Misoprostol revealed that most of them 
believed it to be as effective as oxytocin but stated 
18that maternal and foetal side effects were common . 
The incidence of neonatal asphyxia (where reported) 
17-22ranged between 2.5%and 12.3% .  Unfortunately 
there are no statistics about the use of Misoprostol for 
induction by informal health providers (i.e. nurses, 
traditional and other birth attendants). Yet these birth 
attendants provide the majority of care for women in 
Nigeria and other resource constrained settings. This 
report shows that they do use Misoprostol but details 
about usage in most cases are unknown. 
Introducing widespread community distribution of 
Misoprostol (in a standard dose of 600mcg for PPH) 
could lead to   inadvertent use before delivery and 
increase the frequency of neonatal asphyxia, 
stillbirth and the risks associated with twin 
11
delivery . Further there may be confusion about 
136
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doses to be used in induction with catastrophic 
results as shown in this report. The recent 
introduction into the market of Misoprostol 25 mcg 
tablets may make this confusion worse because the 
colour, size, shape and packaging of the low dose 
formulation is almost identical to that of the 
commonly available 200mcg formulation. Further as 
the price difference between the two formulations is 
small, untrained birth attendants might prefer to buy 
the 200 mcg tablets in order to “obtain better value 
for money” and then use the higher formulation for 
induction. This potential for misuse is one reason 
why WHO is cautious about advocating for 
12
community distribution of Misoprostol .  However 
Misoprostol is readily available without prescription 
1
though it is registered as a prescription only drug . It 
is likely that eventually it will be widely used in the 
community. There is thus an urgent need to train birth 
attendants not only in the public and formal health 
sector but also in the private and informal sectors.  
They need to be aware of the contraindications to use 
of Misoprostol. For example it is contraindicated in 
women who have had previous caesarean delivery 
(and there are many in the community) because it is 
associated with a higher frequency of uterine 
14rupture . This report shows that Birth attendants also 
need to be able identify those neonates that need 
early referral for specialist care.
It is recommended that the Society for Gynaecology 
and Obstetrics (SOGON) in conjunction with the 
Federal Ministry of Health, National Association of 
Nigerian Nurses and Midwives (NANNM) should 
develop guidelines for the use of Misoprostol in 
different levels of healthcare. Training should be 
followed by research into the effect on health 
provider performance, maternal and neonatal 
outcomes as performance change is not always 
automatic and new interventions may need to be 
23developed . Research is also needed to determine 
the benefits and the problems associated with 
widespread community distribution of Misoprostol. 
Doctors who see neonates with birth asphyxia should 
routinely ask about use of Misoprostol in their 
mothers. Efforts should also be made to set up ''no 
blame'' confidential enquiries into birth asphyxia in 
orthodox health facilities and in communities as is 
24
done in some countries . Hopefully these will 
translate into improved training programs and better 
allocation of resources for health care.
In conclusion there is need for development of 
clinical guidelines, training of health providers, 
research at community and facility level, and 
production of low dose Misoprostol formulations 
which can be clearly identified. This would help 
ensure safe and effective use of this promising drug.
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